Inhibrx Biosciences, Inc. (INBX)Healthcare | Biotechnology | La Jolla, United States | NasdaqGS
123.41 USD
-0.52
(-0.420%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 123.41 |
Hot Take ↕ | Aug. 22, 2026, 5:17 a.m. EDT
The immediate catalyst here is a classic biotech binary event: the HexAgon study results. While the company is fundamentally distressed—burning cash, reporting losses, and carrying a net debt position—the market is pricing in a 'lottery ticket' scenario rather than a value play. The stock has nearly doubled in the last year, yet the options chain screams for further explosive gains, with traders positioning for a 100%+ move to hit the $200 strike. This disconnect between the weak fundamentals and the aggressive options positioning suggests the market is ignoring the balance sheet risks in favor of a potential blockbuster drug approval. However, without a dividend or stable cash flow, this remains a high-risk speculation where the thesis relies entirely on the next clinical trial succeeding; if the data is merely 'promising' rather than definitive, the gap between the current price and the lofty analyst targets will likely collapse. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.087860 |
| AutoARIMA | 0.087883 |
| MSTL | 0.090446 |
| AutoTheta | 0.115395 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 11.30 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.012 |
| Excess Kurtosis | 0.78 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 1,816,306,432 |
| Forward P/E | -14.09 |
| Beta | 3.52 |
| Website | https://inhibrx.com |
As of Aug. 22, 2026, 5:17 a.m. EDT: Speculators are aggressively betting on a massive upside move, evidenced by heavy call volume at deep out-of-the-money strikes ($200) for November 2026 and significant new flow into deep out-of-the-money puts ($75) for January 2027. This creates a distinct 'long gamma' bias where traders expect a sharp rally to unlock value, while the lack of in-the-money put volume suggests downside protection is viewed as less critical than the potential for a speculative surge.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.4869661 |
| Address1 | 11,025 North Torrey Pines Road |
| Address2 | Suite 140 |
| All Time High | 155.29 |
| All Time Low | 10.8 |
| Ask | 153.94 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 319,200 |
| Average Daily Volume3 Month | 301,196 |
| Average Volume | 301,196 |
| Average Volume10Days | 319,200 |
| Beta | 3.521 |
| Bid | 125.46 |
| Bid Size | 1 |
| Board Risk | 8 |
| Book Value | -3.602 |
| City | La Jolla |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 123.41 |
| Current Ratio | 5.067 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 126.04 |
| Day Low | 119.38 |
| Display Name | Inhibrx Biosciences |
| Earnings Timestamp End | 1,794,600,000 |
| Earnings Timestamp Start | 1,794,600,000 |
| Ebitda | -125,604,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -14.906 |
| Enterprise Value | 1,872,241,664 |
| Eps Current Year | -8.93 |
| Eps Forward | -8.76 |
| Eps Trailing Twelve Months | -8.88 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 93.6073 |
| Fifty Day Average Change | 29.802704 |
| Fifty Day Average Change Percent | 0.31838012 |
| Fifty Two Week Change Percent | 348.69662 |
| Fifty Two Week High | 155.29 |
| Fifty Two Week High Change | -31.87999 |
| Fifty Two Week High Change Percent | -0.20529327 |
| Fifty Two Week Low | 26.19 |
| Fifty Two Week Low Change | 97.22 |
| Fifty Two Week Low Change Percent | 3.7121038 |
| Fifty Two Week Range | 26.19 - 155.29 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,716,989,400,000 |
| Float Shares | 8,638,825 |
| Forward Eps | -8.76 |
| Forward P E | -14.087899 |
| Free Cashflow | -85,104,872 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 109 |
| Fullday Change | -0.519997 |
| Fullday Change Percent | -0.419589 |
| Fullday Price | 123.41 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -103,000,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.23084 |
| Held Percent Institutions | 0.91072 |
| Implied Shares Outstanding | 14,717,660 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-08-19 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California. |
| Long Name | Inhibrx Biosciences, Inc. |
| Market | us_market |
| Market Cap | 1,816,306,432 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_563995161 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -138,180,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,823,370,897 |
| Number Of Analyst Opinions | 3 |
| Open | 123.8 |
| Operating Cashflow | -131,889,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 858 795 4220 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 123.41 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 123.93 |
| Price Eps Current Year | -13.819709 |
| Price Hint | 2 |
| Price To Book | -34.261524 |
| Price To Sales Trailing12 Months | Infinity |
| Profit Margins | 0.0 |
| Quick Ratio | 4.756 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -0.519997 |
| Regular Market Change Percent | -0.419589 |
| Regular Market Day High | 126.04 |
| Regular Market Day Low | 119.38 |
| Regular Market Day Range | 119.38 - 126.04 |
| Regular Market Open | 123.8 |
| Regular Market Previous Close | 123.93 |
| Regular Market Price | 123.41 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 241,480 |
| Return On Assets | -0.43611 |
| Return On Equity | -17.735981 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 14,717,660 |
| Shares Percent Shares Out | 0.2185 |
| Shares Short | 3,215,230 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 3,433,872 |
| Short Name | Inhibrx Biosciences, Inc. |
| Short Percent Of Float | 0.2917 |
| Short Ratio | 14.27 |
| Source Interval | 15 |
| State | CA |
| Symbol | INBX |
| Target High Price | 325.0 |
| Target Low Price | 230.0 |
| Target Mean Price | 266.66666 |
| Target Median Price | 245.0 |
| Total Cash | 133,344,000 |
| Total Cash Per Share | 9.06 |
| Total Debt | 181,626,000 |
| Total Revenue | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -8.88 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 87.5538 |
| Two Hundred Day Average Change | 35.8562 |
| Two Hundred Day Average Change Percent | 0.40953335 |
| Type Disp | Equity |
| Volume | 241,480 |
| Website | https://inhibrx.com |
| Zip | 92,037 |